Abstract Details

Title Guillain-Barre Syndrome Clinical Characteristics and Outcomes Among Active Component in the U.S. Military, 2014-2022

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) P7 - Poster Session 7 (8:00 AM-9:00 AM)

Poster/Presentation
Number 9-020

Objective To update risk factors and outcomes in Guillain-Barré Syndrome (GBS) among active component U.S. service members between 2014 and 2022.

Background GBS is an immune-mediated polyradiculoneuropathy associated with antecedent illness or immunization. While previous studies suggested a higher incidence in the military, a comprehensive update was needed.

Design/Methods Retrospective review of Defense Medical Surveillance System (DMSS) data identified 191 confirmed GBS cases. Incidence rates, clinical characteristics, electrodiagnostic findings, treatment, and long-term outcomes (Modified Rankin Scale (MRS), chronic pain) were analyzed. Multivariable logistic regression assessed independent associations with outcomes.

Results The incidence rate was 1.6 cases per 100,000 person-years, higher in males (1.7), those under 20 (3.6), and those in basic training status (11.5). Preceding illness noted in 49.2% and preceding immunization within 30 days in 14.7%. Pain was reported in 73.8%. At the acute nadir, 23.6% of cases had moderate to severe disability with an MRS of 4 or 5. At one year follow-up, 51% returned to baseline. There was no association between persistent disability and associated preceding event (e.g. infection or immunization). Chronic pain associated with GBS diagnosis was seen in 28% of patients. Axonal/mixed electrodiagnostic results were associated with greater disability at one year. Acute neuropathic pain treatment predicted poorer functional outcomes and increased risk of chronic pain.

Conclusions GBS in the military population shares similar incidence to civilian cohorts, with certain groups at increased risk. Significant morbidity exists, with chronic pain being a major factor. Early neuropathic pain treatment predicted poorer long-term outcomes. Although recruits had higher incidence, they did not have a higher risk of long-term morbidity.

Authors/Disclosures
Emily Elliott, DO (NAMI) PRESENTER	Dr. Elliott has nothing to disclose.
Cole P. Denkensohn, MD (LRMC)	Dr. Denkensohn has nothing to disclose.
Shauna Stahlman, PhD	Dr. Stahlman has nothing to disclose.
Brittany Watson, PhD	Dr. Watson has received personal compensation for serving as an employee of Life Molecular Imaging.
Kaye E. Sedarsky, MD (Walter Reed National Military Medical Center)	Dr. Sedarsky has nothing to disclose.

��ɫ��

��ɫ��